Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol
,
Mieke Van Hemelrijck,
Muhammad Imran Omar,
Jihong Zong,
Emma Smith,
Katharina Beyer,
Lisa Moris,
Michael Lardas,
Anna Haire,
Francesco Barletta,
Simone Scuderi,
Eleni Vradi,
Giorgio Gandaglia,
Steven MacLennan,
Bahman Farahmand,
Sara J Maclennan,
Zsuzsanna Devecseri,
Alex Asiimwe,
Laurence Collette,
Anders Bjartell,
James Ndow,
Alberto Briganti
Affiliations
4Association of British Neurologists
Mieke Van Hemelrijck
Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King`s College London, Guy`s Hospital, London, UK
Muhammad Imran Omar
Academic Urology Unit, University of Aberdeen, Aberdeen, UK
Jihong Zong
Global Medical Affairs Oncology, Real World Evidence, Bayer HealthCare Pharmaceuticals Inc, Whippany, New Jersey, USA
Emma Smith
UCB, Slough, UK
Katharina Beyer
Translational and Oncology Research (TOUR), King’s College London, Faculty of Life Sciences and Medicine, London, UK
Lisa Moris
Department of Urology, University Hospitals Leuven, Leuven, Belgium
Michael Lardas
Department of Urology, Metropolitan Hospital, Athens, Greece
Anna Haire
Translational Oncology and Urology Research, King`s College London, London, UK
Francesco Barletta
Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
Simone Scuderi
Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
Eleni Vradi
Bayer AG, Berlin, Germany
Giorgio Gandaglia
Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
Steven MacLennan
Academic Urology Unit, University of Aberdeen, Aberdeen, UK
Bahman Farahmand
Global Epidemiology, Bayer AG, Stockholm, Sweden
Sara J Maclennan
Academic Urology Unit, Health Services Research Unit, University of Aberdeen, Aberdeen, Aberdeen, UK
Zsuzsanna Devecseri
Sanofi, Paris, France
Alex Asiimwe
Bayer AG, Berlin, Germany
Laurence Collette
EORTC Headquarters, Brussels, Belgium
Anders Bjartell
Skåne University Hospital, Malmö, Sweden
James Ndow
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
Alberto Briganti
5 Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Lombardia, Italy
Introduction As part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).Methods and analysis This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required.Ethics and dissemination We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.
